NeuroVive Pharmaceutical AB año OPV
¿Qué es el año OPV de NeuroVive Pharmaceutical AB?
El año OPV de NeuroVive Pharmaceutical AB es 2018
¿Cuál es la definición de año OPV?
La oferta pública inicial es un tipo de oferta pública en la cual las acciones de una compañía generalmente se venden a inversionistas institucionales que, a su vez, venden al público en general, en una bolsa de valores, por primera vez.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
año OPV de compañías en Sector Health Care en OTC en comparadas con NeuroVive Pharmaceutical AB
¿Qué hace NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Empresas con año opv similar a NeuroVive Pharmaceutical AB
- Mediawan SA tiene año OPV de 2017
- Southern tiene año OPV de 2017
- Polytec Hldg Ag Inh. Eo 1 tiene año OPV de 2017
- Roots Sustainable Agricultural Technologies tiene año OPV de 2017
- Galena Mining tiene año OPV de 2017
- MVC Capital Inc tiene año OPV de 2017
- NeuroVive Pharmaceutical AB tiene año OPV de 2018
- Bermele plc tiene año OPV de 2019
- Twin River Worldwide tiene año OPV de 2019
- Contel Technology tiene año OPV de 2019
- GraniteShares 3x Long Diageo Daily ETC tiene año OPV de 2019
- Pinterest Inc tiene año OPV de 2019
- Ferrellgas Partners, L.P tiene año OPV de 2019